Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2016-03-21 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the completion of the Phase 2 trial design for their lead compound hCDR1 and plans to file an IND with the FDA. It is a regulatory update about clinical trial progress and plans, not a full financial report or earnings release. The document is about operational and clinical development updates rather than financial results or governance changes. Form 6-K filings are typically regulatory filings for foreign issuers to report material information between annual reports. The document length is about 9751 characters, which is consistent with a detailed regulatory announcement but not a full annual or quarterly report. There is no detailed financial data or management discussion of financial results. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-03-21 English
Immediate Report
Board/Management Information Classification · 95% confidence The document is explicitly titled "Form 6-K" and is filed with the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION." Form 6-K is the standard filing for a Foreign Private Issuer to report material information to the SEC, often used to disseminate press releases or other information that is required to be made public in the home country or exchange. The content is a press release announcing the appointment of a new Medical Director and providing updates on clinical trials for their lead product. This type of material, when filed on Form 6-K, is generally classified as a general regulatory announcement or a specific type of report depending on the content. Since the content is a press release announcing management/personnel changes and clinical updates, it doesn't perfectly fit the specific categories like MANG (which is usually just board/senior management *change* announcement) or ER/IR (which are financial results). Given that Form 6-K is a broad mechanism for foreign issuers to report material events, and the content is a press release, the most appropriate general category for non-standard, material announcements that aren't explicitly covered elsewhere (like earnings or definitive proxy statements) is the Regulatory Filings fallback (RNS), as 6-K filings often serve this purpose for foreign companies. However, since the content is a press release announcing a key management appointment (Medical Director), it strongly aligns with 'Board/Management Information' (MANG). Since the document is the full press release itself, not just an announcement *about* the release, MANG is a strong candidate. Let's re-evaluate the definitions. MANG is for 'Announcement of changes in the company's board of directors or senior management.' Appointing a Medical Director fits this description. While it's filed on a 6-K, the *substance* is management change. I will classify it as MANG based on content substance over the form type, as the definitions prioritize content type (e.g., ER, IR, MANG).
2016-03-09 English
Immediate Report
Board/Management Information Classification · 98% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000). The content explicitly states: 'Attached hereto is a report on the appointment of Dr. Daphna Paran, an internal medicine and rheumatology specialist, as Medical Director.' This describes a change in senior management/personnel. This aligns directly with the definition for Board/Management Information (MANG). Although it mentions an attachment (PDF), the core purpose of this filing is the announcement of the management change itself, not just the publication of a report, making MANG more specific than RPA or RNS.
2016-03-09 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It contains a corporate announcement about the appointment of a new Medical Director and information about the company's lead drug candidate and clinical plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement of corporate developments rather than a financial report or earnings release. Form 6-K filings typically serve as regulatory filings for foreign issuers to disclose material information. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 9489 characters, which is substantial but the content is primarily a corporate announcement and not a financial report or presentation.
2016-03-09 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It is a report pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for the month of March 2016. The content is a press release announcing the expansion of the company's global IP portfolio with a patent issued in Hungary for their lupus drug hCDR1. The document includes forward-looking statements and contact information but does not contain financial statements or detailed financial analysis. It is a regulatory filing reporting material corporate news rather than a full financial report or earnings release. Given the nature of Form 6-K filings, which are used by foreign private issuers to report material information to the SEC, and the content being a corporate announcement, the appropriate classification is Regulatory Filings (RNS). The document length (8223 characters) and content confirm it is not a brief announcement of a report (RPA) nor a full annual or interim report. Therefore, the classification is RNS with high confidence.
2016-03-02 Hebrew (modern)
Immediate Report
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The core content announces the 'receiving a patent from the Hungarian Intellectual Property Office' and explicitly mentions an attached PDF file ('02_03_16_XTLB_6K_isa.pdf'). Since the document itself is short (1863 chars) and serves primarily to announce the availability of information regarding a legal/intellectual property matter (a patent grant), it fits the description of a general regulatory announcement that doesn't fit a more specific financial report category. While it relates to Intellectual Property (IP), the structure strongly suggests a mandatory regulatory disclosure about a specific event rather than the full IP document itself. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, immediate regulatory disclosure that isn't a standard financial report (10-K, IR, ER) or a specific legal proceeding update (LTR), although it touches upon IP. However, upon reviewing the definitions, the content is about receiving a patent, which is a form of intellectual property news. Since 'IP' (Investor Presentation) is not the right fit, and 'LTR' (Legal Proceedings Report) usually covers lawsuits/regulatory actions, 'RNS' (Regulatory Filings) serves as the best general category for this type of immediate, non-financial report announcement.
2016-03-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.